Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -271.53% is 27% above its 5-year average of -373.37%, near the high end of its 5-year range (-7136.00%–85.85%).
63.51% above its 12-month average of -744.06%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -2180.93%.
EBITDA MARGIN
-271.53%
EBITDA MARGIN AVG TTM
-744.06%
EBITDA MARGIN AVG 3Y
-372.56%
EBITDA MARGIN AVG 5Y
-373.37%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+63.51%
CURRENT VS 3Y AVG
+27.12%
CURRENT VS 5Y AVG
+27.28%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Opus Genetics, Inc.
Market Cap
$364.83M
EBITDA Margin
-271.53%
TTM Avg
-744.06%
3Y Avg
-372.56%
5Y Avg
-373.37%
Market Cap
$357.96M
EBITDA Margin
-122.86%
TTM Avg
-149.66%
3Y Avg
-152.47%
5Y Avg
-125.05%
Market Cap
$356.37M
EBITDA Margin
18.25%
TTM Avg
18.77%
3Y Avg
18.63%
5Y Avg
20.30%
Market Cap
$356.07M
EBITDA Margin
-1371.56%
TTM Avg
-1336.69%
3Y Avg
-1827.03%
5Y Avg
-11314.18%
Market Cap
$353.48M
EBITDA Margin
-25837.05%
TTM Avg
-12960.93%
3Y Avg
-7440.06%
5Y Avg
-7440.06%
Market Cap
$355.09M
EBITDA Margin
-153.75%
TTM Avg
-1289.79%
3Y Avg
-1338.35%
5Y Avg
-1135.96%
Market Cap
$355.01M
EBITDA Margin
-13.98%
TTM Avg
-3.54%
3Y Avg
-384.69%
5Y Avg
-2364.58%
Market Cap
$376.10M
EBITDA Margin
-12.87%
TTM Avg
-20.20%
3Y Avg
-216.20%
5Y Avg
-209.97%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Opus Genetics, Inc. (IRD) | $364.83M | -271.53% | -744.06% | -372.56% | -373.37% |
| Embecta Corp. (EMBC)vs › | $358.05M | 35.21% | 27.25% | 28.55% | 34.67% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $357.96M | -122.86% | -149.66% | -152.47% | -125.05% |
| Viemed Healthcare, Inc. (VMD)vs › | $356.37M | 18.25% | 18.77% | 18.63% | 20.30% |
| Ocugen, Inc. (OCGN)vs › | $356.07M | -1371.56% | -1336.69% | -1827.03% | -11314.18% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $353.48M | -25837.05% | -12960.93% | -7440.06% | -7440.06% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $355.09M | -153.75% | -1289.79% | -1338.35% | -1135.96% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $355.01M | -13.98% | -3.54% | -384.69% | -2364.58% |
| Canopy Growth Corporation (CGC)vs › | $376.10M | -12.87% | -20.20% | -216.20% | -209.97% |
| YD Bio Limited Ordinary Shares (YDES)vs › | $376.11M | -848.19% | -557.06% | -372.08% | -372.08% |
Gross Margin
99.9%
EBITDA Margin
-271.5%
Operating Margin
-271.9%
Net Margin
-1091.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -2180.93% |
| 2026-03-31 | -665.32% |
| 2025-12-31 | -295.99% |
| 2025-09-30 | -269.50% |
| 2025-06-30 | -308.54% |
| 2025-03-31 | -226.91% |
| 2024-12-31 | -883.93% |
| 2024-09-30 | -207.11% |
| 2024-06-30 | -748.92% |
| 2024-03-31 | -450.50% |
| 2023-12-31 | -320.88% |
| 2023-09-30 | 53.51% |
| 2023-06-30 | -146.65% |
| 2023-03-31 | -350.49% |
| 2022-12-31 | 85.85% |
| 2021-09-30 | -865.24% |
| 2021-06-30 | -7136.00% |
